3-year-old Vania has blood cancer

Vania Gezik is a happy, cheerful and energetic kid. Clever and inquisitive loves to play cars. And how can sit still when there is so much interesting around? the trouble in this family came unexpectedly. In December last year, Vanya passed a medical examination in front of a kindergarten. But the result of the blood test of Vanya very worried doctors and the child was sent to the hematology department of the Dnipropetrovsk Children's Clinical Hospital. The boy passed the necessary examinations. And the result of bone marrow puncture stunned his mother: a kid has blood cancer... 

Thus began the daily struggle for the life of little Vanya. The child is prescribed chemotherapy. It is difficult for the baby to tolerate "chemistry": blood counts are falling, hepatic rates are "jumping", and leukocytes are very low. The boy becomes weak and irritable.
To restore liver function, the child badly needs the preparation Heptral, two packs of which cost 2,330 UAH. For the stimulation of leukocytes, the child needs a colony-stimulating preparation Neupogen in the quantity of 1 pack (5 syringes) worth 7 825 UAH. The cost of these drugs is huge for Vania’s mom, but a child cannot be left without treatment.

Vania was born in the town of Kamianske, Dnipropetrovsk region. The father left the family and one mother brings up two small children: Vania and his four-year-old sister Valeria. The girl now lives with her grandmother and misses Vania very much. There is also an adult daughter, whose son is also growing up. It is very difficult for a mother to cope with all the costs associated with the treatment of the son, the father almost does not help financially with their children. Relatives and acquaintances help, but there is not enough money for everything. To save the baby, the mother is forced to ask for help to all caring people: please help in treating her son! Please support Vanya!

Name: Gezik Ivan, 26.12.2015

City: Kamianske, Dnepropetrovsk region 

Diagnosis: acute lymphoblastic leukemia, L1 common, high-risk group, I acute period, bone marrow remission